Details of the Drug Combination

General Information of Drug Combination (ID: DC5HNGZ)

• Drug Combination Name: Lithium Citrate + BIO-300
• Indication: Chronic myelogenous leukemia; Status: Investigative [1]
• Component Drugs:
  Lithium Citrate (DMXAVX5): Small molecular drug
  BIO-300 (DMJ7NVI): N.A.
• High-throughput Screening Result:
  Testing Cell Line: KBM-7
  Zero Interaction Potency (ZIP) Score: 1.69
  Bliss Independence Score: 1.69
  Loewe Additivity Score: 2.3
  LHighest Single Agent (HSA) Score: 2.3

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Clinical pipeline report, company report or official report of Humanetics.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)